Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-024913
Filing Date
2025-05-13
Accepted
2025-05-13 08:08:23
Documents
73
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ovid-20250331.htm   iXBRL 10-Q 1234516
2 EX-31.1 ovid2025q1exhibit311.htm EX-31.1 10719
3 EX-31.2 ovid2025q1exhibit312.htm EX-31.2 10756
4 EX-32.1 ovid2025q1exhibit321.htm EX-32.1 6032
10 ovid-20250331_g1.jpg GRAPHIC 136221
  Complete submission text file 0001628280-25-024913.txt   6719947

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20250331.xsd EX-101.SCH 49826
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ovid-20250331_cal.xml EX-101.CAL 62078
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20250331_def.xml EX-101.DEF 206663
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20250331_lab.xml EX-101.LAB 627560
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20250331_pre.xml EX-101.PRE 424941
76 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20250331_htm.xml XML 649286
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 25937255
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)